ArticleEuropean urology open science2026
Adoption of MRI-guided Prostate Cancer Diagnostics and Surgical Outcomes: A Prospective Multicenter Registry Study.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adoption of magnetic resonance imaging (MRI)-guided prostate biopsy across different health care settings remains variable, and its implementation, following guideline endorsement, has not been fully characterized, particularly with respect to temporal trends and downstream surgical outcomes. Design setting and participants: We analyzed biopsy techniques and postoperative outcomes among men undergoing radical prostatectomy (2020-2025), using the prospective national SWISS urology prostatectomy registry. Outcome measurements and statistical analysis: Temporal trends in MRI-guided versus non-MRI-guided biopsy were compared across university, regional, and local/private hospitals. Multivariable logistic regression models were used to evaluate associations between biopsy technique and pathological and perioperative outcomes. Results and limitations: A total of 7687 men from 29 centers were included. A rapid transition from non-MRI-guided to MRI-guided biopsy was observed over the study period. University hospitals were early adopters of MRI-guided biopsy, with use approaching 85% by 2020 and achieving complete adoption by 2024. Regional and local/private hospitals showed a more gradual increase, with MRI-guided biopsy rising from 44% in 2020 to 88% by early 2025. In multivariable analyses, MRI-guided biopsy was associated with lower risk of understaging (odds ratio [OR] 0.64; 95% confidence interval [CI] 0.57-0.72; Conclusions: MRI-guided biopsy rapidly became the dominant diagnostic approach, with academic centers leading adoption and other care settings converging thereafter, highlighting the important role of academic centers in implementing guideline-recommended diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.